Xenetic Biosciences (XBIO) Stock: Buy, Sell, or Hold?
XBIO - Xenetic Biosciences, Inc.
$3.90
-0.17 (-4.18%)
▼
5d:
-15.77%
30d:
+18.18%
90d:
+30.0%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 11, 2026
0d
Get Alerted When XBIO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: XBIO is down 15.8% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: XBIO is down 15.8% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: XBIO is currently trading at $3.90, which is considered fair relative to its 30-day fair value range of $3.19 to $4.20.
Technical Outlook: Technically, XBIO is in a uptrend. The price is currently testing key support at $3.84. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.2% recently.
Market Sentiment: XBIO scores 8/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $40.00 (+925.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, XBIO is in a uptrend. The price is currently testing key support at $3.84. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.2% recently.
Market Sentiment: XBIO scores 8/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $40.00 (+925.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$3.19 -
$4.20
Company Quality Score
37/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
44.7%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (8/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.2%)
- BULLISH: Trading 925.6% below Wall St target ($40.00)
- WARNING: Composite score 36/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$3.19 -
$4.20
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$3.84
Resistance Level
$4.94
Current Trend
Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-11.47
Wall Street Target
$40.00
(+925.6%)
Revenue Growth (YoY)
12.0%
Profit Margin
-75.9%
Share & Embed Analysis
Last updated: September 13, 2026 11:04 AM ET
Data refreshes hourly during market hours. Next update: 12:04 PM
Data refreshes hourly during market hours. Next update: 12:04 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is XBIO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 45 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$128 | 50 HOLD |
|
ACAD
ACADIA Pharmaceuticals I… |
BUY
20 analysts |
$34 | 52 HOLD |
|
JSPR
Jasper Therapeutics Inc |
STRONG BUY
11 analysts |
$7 | 62 BUY |
|
RLAY
Relay Therapeutics Inc |
STRONG BUY
13 analysts |
$27 | 64 BUY |
